Another trade headache, now in Switzerland
The U.S. could open a trade investigation into Switzerland’s pharmaceutical industry, according to the head of Swiss industry body Interpharma. That would echo the investigation launched last week against Germany, which is a pretty clear sign Washington is keeping its microscope on foreign drugmakers.
Why investors should care
Trade probes are not just bureaucratic busywork. They can turn into tariffs, pricing pressure, supply-chain headaches, and a whole lot of uncertainty for companies that depend on smooth cross-border flows. For pharma, where margins and global manufacturing are already doing enough gymnastics, that’s not exactly a fun new plot twist.
The bigger picture
If this escalates, the real story won’t just be Switzerland. It’ll be whether the U.S. is widening its trade scrutiny across European pharma more broadly. And when policymakers start playing whack-a-mole with one industry across multiple countries, you know the sector is in for a choppy stretch.
Big picture: even the threat of an investigation can be enough to keep investors in wait-and-see mode, because in trade wars, the opening scene is often the most expensive part.